BACKGROUND: Transcatheter aortic valve implantation (TAVI) represents a significant development in the treatment of high risk patients with aortic stenosis. As one of the first centers to perform transapical TAVI (taTAVI), we herein review our five-year experience with this technique. METHODS: All patients undergoing taTAVI with an Edwards Sapien valve at the Leipzig Heart Center between 2006 and 2011 (n=439) were analysed. Data was drawn from a prospective database and retrospectively analysed. The learning curve was reviewed by means of descriptive statistics as well as cumulative sum failure analysis (CUSUM). All results are presented in compliance with Valve Academic Research Consortium (VARC) criteria. RESULTS: The mean patient age was 81.5±6.4 years and 64.0% were female. The mean logistic EuroSCORE and STS risk of mortality were 29.7%±15.7% and 11.4%±7.6%, respectively. Procedural success was 90.2%. Stroke occurred in 2.1% of patients intra-operatively and a further 2.1% suffered stroke during their hospital stay. Mean transvalvular gradient was 9.0±3.9 mmHg and effective valve orifice area 1.3±0.6 cm(2). Moderate or greater aortic insufficiency was present in 5.7% of patients and remained stable during follow up. Overall survival was 90% at 30 days, 73% at 1 year, 68% at 2 years, 58% at 3 years, 53% at 4 years, and 44% at 5 years. CUSUM analysis revealed a definitive learning curve regarding the occurrence of major complications, with a progressive improvement after the initial 150 cases. CONCLUSION: TaTAVI has become a routine approach for high risk patients with symptomatic severe aortic stenosis. Although taTAVI is a safe procedure with reproducible results, future research should focus on methods of reducing known complications and the associated learning curve for this procedure.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) represents a significant development in the treatment of high risk patients with aortic stenosis. As one of the first centers to perform transapical TAVI (taTAVI), we herein review our five-year experience with this technique. METHODS: All patients undergoing taTAVI with an Edwards Sapien valve at the Leipzig Heart Center between 2006 and 2011 (n=439) were analysed. Data was drawn from a prospective database and retrospectively analysed. The learning curve was reviewed by means of descriptive statistics as well as cumulative sum failure analysis (CUSUM). All results are presented in compliance with Valve Academic Research Consortium (VARC) criteria. RESULTS: The mean patient age was 81.5±6.4 years and 64.0% were female. The mean logistic EuroSCORE and STS risk of mortality were 29.7%±15.7% and 11.4%±7.6%, respectively. Procedural success was 90.2%. Stroke occurred in 2.1% of patients intra-operatively and a further 2.1% suffered stroke during their hospital stay. Mean transvalvular gradient was 9.0±3.9 mmHg and effective valve orifice area 1.3±0.6 cm(2). Moderate or greater aortic insufficiency was present in 5.7% of patients and remained stable during follow up. Overall survival was 90% at 30 days, 73% at 1 year, 68% at 2 years, 58% at 3 years, 53% at 4 years, and 44% at 5 years. CUSUM analysis revealed a definitive learning curve regarding the occurrence of major complications, with a progressive improvement after the initial 150 cases. CONCLUSION: TaTAVI has become a routine approach for high risk patients with symptomatic severe aortic stenosis. Although taTAVI is a safe procedure with reproducible results, future research should focus on methods of reducing known complications and the associated learning curve for this procedure.
Authors: Thomas Walther; Volkmar Falk; Michael A Borger; Todd Dewey; Gerhard Wimmer-Greinecker; Gerhard Schuler; Michael Mack; Friedrich W Mohr Journal: Eur J Cardiothorac Surg Date: 2006-11-09 Impact factor: 4.191
Authors: David M Holzhey; Stephan Jacobs; Thomas Walther; Michael Mochalski; Friedrich W Mohr; Volkmar Falk Journal: J Thorac Cardiovasc Surg Date: 2007-09 Impact factor: 5.209
Authors: Neil E Moat; Peter Ludman; Mark A de Belder; Ben Bridgewater; Andrew D Cunningham; Christopher P Young; Martyn Thomas; Jan Kovac; Tom Spyt; Philip A MacCarthy; Olaf Wendler; David Hildick-Smith; Simon W Davies; Uday Trivedi; Daniel J Blackman; Richard D Levy; Stephen J D Brecker; Andreas Baumbach; Tim Daniel; Huon Gray; Michael J Mullen Journal: J Am Coll Cardiol Date: 2011-10-20 Impact factor: 24.094
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Corrado Tamburino; Davide Capodanno; Angelo Ramondo; Anna Sonia Petronio; Federica Ettori; Gennaro Santoro; Silvio Klugmann; Francesco Bedogni; Francesco Maisano; Antonio Marzocchi; Arnaldo Poli; David Antoniucci; Massimo Napodano; Marco De Carlo; Claudia Fiorina; Gian Paolo Ussia Journal: Circulation Date: 2011-01-10 Impact factor: 29.690
Authors: Samuel V Lichtenstein; Anson Cheung; Jian Ye; Christopher R Thompson; Ronald G Carere; Sanjeevan Pasupati; John G Webb Journal: Circulation Date: 2006-07-31 Impact factor: 29.690
Authors: Martyn Thomas; Gerhard Schymik; Thomas Walther; Dominique Himbert; Thierry Lefèvre; Hendrik Treede; Holger Eggebrecht; Paolo Rubino; Iassen Michev; Rüdiger Lange; William N Anderson; Olaf Wendler Journal: Circulation Date: 2010-06-21 Impact factor: 29.690
Authors: Sabine Bleiziffer; Hendrik Ruge; Domenico Mazzitelli; Andrea Hutter; Anke Opitz; Robert Bauernschmitt; Rüdiger Lange Journal: J Thorac Cardiovasc Surg Date: 2009-09-17 Impact factor: 5.209
Authors: Gerhard Schymik; Valentin Herzberger; Jens Bergmann; Peter Bramlage; Lars O Conzelmann; Alexander Würth; Armin Luik; Holger Schröfel; Panagiotis Tzamalis Journal: BMJ Open Date: 2018-10-25 Impact factor: 2.692